Electromedical & Electrotherapeutic Apparatus
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Discounted Cash Flow Valuation of Conmed Corp
Growth
%
%
Discount
%
%
Multiple
g\r | +10% | +11% | +12% | +13% | +14% |
---|---|---|---|---|---|
0% | 10 | 9 | 8 | 8 | 7 |
+1% | 11 | 10 | 9 | 8 | 8 |
+2% | 13 | 11 | 10 | 9 | 8 |
+3% | 14 | 13 | 11 | 10 | 9 |
+4% | 17 | 14 | 12 | 11 | 10 |
Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF | $141.5M | $154.1M | $167.1M | $180.6M | $194.3M | $208.2M | $222.2M | $236.2M | $250.1M | $263.6M | $276.8M | $2.768B |
DCF | $134M | $126.4M | $118.7M | $111.1M | $103.5M | $96.06M | $88.79M | $81.74M | $74.94M | $68.42M | $684.2M | |
Value | $1.688B |
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Margin | 4.2% | 1.9% | 7% | 4.8% | 3% | 1.1% | 6.2% | -7.7% | 5.2% | 6.5% |
ROA | 4.6% | 2.8% | 3.5% | 5.2% | 4.5% | 2.6% | 6.2% | 3% | 5.2% | 6.2% |
ROE | 5.2% | 2.5% | 8.8% | 6.2% | 4% | 1.3% | 8% | -11% | 7.7% | 9.6% |
The average Net Margin over the past 5 years is +2.09%.
The trend of Net Margin over the past 5 years is -0.71%.
The average ROA over the past 5 years is +4.47%.
The trend of ROA over the past 5 years is -0.01%.
The average ROE over the past 5 years is +2.74%.
The trend of ROE over the past 5 years is -0.86%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | 8.23 | 21.68 | 9.51 | 8.17 | 10.42 | 14.99 | 7.19 | 97.11 | 9.17 | 7.01 |
Debt Equity | 0.47 | 0.88 | 0.79 | 0.72 | 1.10 | 1.09 | 0.89 | 1.51 | 1.17 | 1.16 |
MIN | ||||||||||
Graham Stability | - | - | 100% | 100% | 77% | 23% | 100% | -240% | - | -240% |
The Debt/FCF trailing twelve month is 7.01.
The trend of Debt/FCF over the past 5 years is 7.35.
Graham’s Stability measure stands at -2.40.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
---|---|---|---|---|---|
Revenue | 7.2% | 7.7% | 13% | 19% | 1.5% |
Net Income | 24% | 9.5% | 89% | - | 48% |
Stockholders Equity | 5.3% | 4.7% | 5.6% | 12% | 0.52% |
FCF | 24% | 13% | 27% | 820% | 52% |
The Revenue CAGR over the past 5 years is +7.68%.
The trend of Revenue growth rate over the past 5 years is +1.46%.
The Earnings CAGR over the past 5 years is +9.55%.
The trend of Earnings growth rate over the past 5 years is +48.19%.
The Equity CAGR over the past 5 years is +4.72%.
The trend of Equity growth rate over the past 5 years is +0.52%.
The FCF CAGR over the past 5 years is +12.81%.
The trend of FCF growth rate over the past 5 years is +51.91%.